APL-101 Trial for Advanced Cancer
Phase 2
497
about 9.2 years
18+
6 sites in CA, FL, MA +3
What this study is about
This trial is testing APL-101, an oral capsule treatment, in people with advanced cancers. The goal is to see if APL-101 helps treat NSCLC (lung cancer) with specific MET mutations and other solid tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take APL-101 Oral Capsules
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
oral
Primary: Objective response rate (ORR = CR + PR) per IRC committee (BIRC) based on RECIST v1.1 (or relevant criteria per tumor type)
Secondary: Antitumor activity by clinical benefit rate (CR + PR + SD ≥ 4 cycles) based on RECIST v1.1, RANO criteria for CNS tumors, or other relevant criteria per tumor type Median time to progression (TTP)., Median DOR per investigator assessment., Median duration of response (DOR) per IRC., Median time to progression (TTP)., ORR per investigator assessment based on RECIST v1.1., Progression Free Survival (PFS) and overall survival (OS) at 6, 12, 18 and 24 months
Oncology